Cost‐effectiveness analysis of hepatitis E vaccination strategies among patients with chronic hepatitis B in China

作者：Tingting Cui, Xuefeng Zhang, Qiang Wang, Na Yue, Changjun Bao, Renjie Jiang, Shilin Xu, Zhaohu Yuan, Yunke Qian, Liling Chen, Hui Hang, Zhong Zhang, Hongmin Sun, Hui Jin · 发表于：Hepatology Research · 年份：2023 · DOI：10.1111/hepr.13967 · 被引用次数：9 · 研究领域：Hepatitis Viruses Studies and Epidemiology、Hepatitis B Virus Studies、Viral gastroenteritis research and epidemiology

AIM: This study aimed to evaluate the cost-effectiveness of hepatitis E vaccination strategies in chronic hepatitis B (CHB) patients. METHODS: Based on the societal perspective, the cost-effectiveness of three hepatitis E vaccination strategies-vaccination without screening, screening-based vaccination, and no vaccination-among CHB patients was evaluated using a decision tree-Markov model, and incremental cost-effectiveness ratios (ICERs) were calculated. Values for treatment costs and health utilities were estimated from a prior investigation on disease burden, and values for transition probabilities and vaccination-related costs were obtained from previous studies and government agencies. Sensitivity analyses were undertaken for assessing model uncertainties. RESULTS: It was estimated that CHB patients superinfected with hepatitis E virus (HEV) incurred significantly longer disease course, higher economic burden, and more health loss compared to those with HEV infection alone (all p < 0.05). The ICERs of vaccination without screening and screening-based vaccination compared to no vaccination were 41,843.01 yuan/quality-adjusted life year (QALY) and 29,147.32 yuan/QALY, respectively, both lower than China's per-capita gross domestic product (GDP) in 2018. The screening-based vaccination reduced the cost and gained more QALYs than vaccination without screening. One-way sensitivity analyses revealed that vaccine price, vaccine protection rate, and decay rate of vaccine protect...